GBI Research, the
leading business intelligence provider, has released its latest
research: “Critical Care Therapeutics in Major Developed Markets to
2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products
to Drive Market”, which provides in-depth analysis of the critical
care market in the US, UK, France, Germany, Italy, Spain, Japan and
Canada.
View Full Report at
http://www.marketresearchreports.biz/analysis/211679
The report provides
an estimation of market size for 2013, along with market forecasts to
2020. It covers critical care indications that are being treated
using the five major plasma-derived products of albumin,
anti-thrombin concentrates, factor XIII concentrates, fibrinogen
concentrates, and prothrombin complex concentrates. The total value
of the critical care market in the major developed markets was
estimated at $1.8 billion in 2013 and is expected to grow at a
Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019.
This growth is attributed to the recent approval of new factor
concentrates in the US that are expected to witness increasing uptake
in the forecast period. Factor concentrates are increasingly
preferred due to their lower infection risks over older alternatives
such as FFP and cryoprecipitate in critical care settings.
Download Detail
Report With Complete TOC at
http://www.marketresearchreports.biz/sample/sample/211679
The US accounts for
the largest share (41%) of the global critical care market and is
expected to post high growth at a CAGR of 7.5% until 2020. KCentra,
the first four-factor PCC in the US, and Tretten, the first
recombinant FXIII concentrate, were approved in 2013 and are expected
to witness good uptake in the forecast period. Two additional factor
concentrates approved in the US in 2009 – RiaStap (human fibrinogen
concentrate) and ATryn (recombinant AT concentrate) – are also
expected to increase their uptake, which will contribute to market
growth. With no new significant launches in the forecast period, the
European market is estimated to witness much slower growth, with the
UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%,
and Italy at 2.0%
Scope
The report analyzes
treatment usage patterns, market characterization, pipeline analysis
and key licensing and co-development deals in critical care in the
eight major developed markets of the US, UK, France, Germany, Italy,
Spain, Japan and Canada.
The report includes:
- A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
- Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
- A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
- Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
- Key drivers and restraints that have had and are expected to have a significant impact on the market
- An overview of major licensing and co-development agreements that could affect growth trends
Reasons to Buy
- The report will enhance your decision-making capability by allowing you to:
- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
- Develop key strategic initiatives based on an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
No comments:
Post a Comment